Finance Watch: VC Mega-Rounds Are Alive And Well
Aspen Neuroscience, MOMA Therapeutics Raised $147.5m And $150m, Respectively
Private Company Edition: Also, Catalio closed a $381m venture capital fund and OrbiMed’s SEC filings indicate it is in the process of raising $4.75bn across three new funds. Dianthus launched with $100m and Tubulis closed a $63m series B round.
You may also be interested in...
Also, Cytovia will go public via SPAC merger, Nkarta capitalized on its positive early NK cell therapy data with a $230m offering, and venture capital mega-rounds include $220m for Reify, $110m for Satellite Bio and $100m for OMass Therapeutics.
Four Chinese RNA technology developers, including Rona Therapeutics and METiS Pharmaceuticals, have bagged the most proceeds in recent financing rounds in the country backed by venture capital and private equity funds.
Apnimed is going to conduct one more Phase II study in sleep apnea, mainly to assess subjective endpoint questionnaires, and then hopes to launch a Phase III program by autumn of 2022.